BNGO Bionano Genomics Inc

Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation in the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting 2024 with a broad range of content covering optical genome mapping’s (OGM) utility for research areas including cancer, rare genetic disease and constitutional disorders. ACMG’s Annual Meeting brings together industry, medical, and academic professionals to discuss advances in clinical genetics research. The ACMG conference will be held March 12-16, 2024, in Toronto, Canada.

All scientific posters will be presented in Exhibit Halls DE. Poster presentations and scientific workshop sessions on OGM include:

Poster Number		Title		Authors	Presented
P573		Genome-wide short tandem repeat expansion screening using optical genome mapping		Yu J.	March 14, 202410:30 AM-12:00 PM ET
P583		Clinical utility of optical genome mapping as an additional test to standard cytogenetic workup of hematological malignancies		Toruner G.	March 14, 202410:30 AM- 12:00 PM ET
P839		A curated research catalogue of structural variation detected by optical genome mapping		Pang A.	March 14, 202410:30 AM-12:00 PM ET
P088		A comprehensive approach to evaluate genetic abnormalities in plasma cell neoplasms using optical genome mapping and next-generation sequencing		Zou Y.	March 15, 202410:30 AM-12:00 PM ET
P608		Optical genome mapping for genome-wide structural variation analysis in hematologic malignancies: results of a prospective study and potential impact on diagnosis and management		Sahoo T.	March 15, 202410:30 AM-12:00 PM ET
P656		Improved diagnostic paradigm using optical genome mapping (OGM) for cytogenomic testing for recurrent pregnancy loss and infertility		Crocker S.	March 15, 202410:30 AM-12:00 PM ET
P694		Case report: unraveling a complex chromosomal rearrangement case using optical genome mapping		Ozcan Z.	March 15, 202410:30 AM- 12:00 PM ET
P742		Assessing stability of frozen samples for Bionano optical single DNA mapping for diagnosis of Facioscapulohumeral Muscular Dystrophy Type 1		Cook S.	March 15, 202410:30 AM-12:00 PM ET
P746		Genome wide, high-throughput, high-resolution structural variation detection at low variant allele fraction for oncology samples		Hastie A.	March 15, 202410:30 AM-12:00 PM ET
P842		Unified comprehensive analysis of NGS and optical genome mapping data for constitutional applications using Bionano VIA™ software		Norgaard Z.	March 15, 202410:30 AM-12:00 PM ET
P850		Accelerated optical genome mapping analysis with Stratys Compute and Guided Assembly		Senol Cali D.	March 15, 202410:30 AM-12:00 PM ET
Session		Title		Presenter	Presented
Sponsored Workshop		LIVE Bionano product showcase – Stratys™ revealed: exclusive first look at the future of OGM		Chaubey A., Broeckel U., Crocker S., Hamadeh Z., Holmlin E., Jiandani D., Levy B., McCready L., Sahoo T.	March 12, 20248:00 AM- 12:30 PM ETDelta Hotel by Marriott- Kensington Ballroom
Plenary Session		2024 ACMG Foundation Awards and Presidential Plenary Session		Holmlin E.	March 13, 202410:00-12:00 PM ETExhibit Hall FG
Platform Presentation		A Canadian lab’s clinical validation experience with optical genome mapping as a front-line diagnostic test for hematological neoplasms		Hamadeh Z., Spence T.	March 14, 20244:15-5:45 PM ETMTCC- 714/716
Sponsored Workshop		Revolutionizing cytogenomics with Stratys™: unveiling a new frontier in structural variant assessment through optical genome mapping at scale		Chaubey A., Spence T.,	March 15, 202410:45-11:15 AM ETExhibit Theater 2

Erik Holmlin, PhD, president and chief executive officer of Bionano, added, “We are proud to debut our new high throughput system for OGM, Stratys, at ACMG this year, and to host sessions featuring customers from our Stratys early access program presenting data from work conducted on the system. Researchers and scientists continue to push forward cutting-edge research in the human genetics space and we believe the capabilities of the Stratys system will unlock even more exciting research advancements. We look forward to these customers sharing their findings with the ACMG community.”

More details on Bionano’s conference events can be found here.

About Bionano

Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. Bionano’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. Bionano offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, Bionano also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Bionano also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. Bionano additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis technology.

Forward-Looking Statements of Bionano

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “potential,” “will,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: OGM’s utility for applications in cancer, rare genetic disease and constitutional disorder research and in the areas reported in the presentations given and the posters made available at ACMG’s 2024 Annual Meeting; the ability of the Stratys system to unlock research advancements; and the growth and adoption of OGM. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of adverse geopolitical and macroeconomic events, such as the ongoing conflicts between Ukraine and Russia and Israel and Gaza and uncertain market conditions, including bank failures, inflation and supply chain disruptions, on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; failure of OGM to prove useful in areas including applications in cancer, rare genetic disease and constitutional disorder research and in the areas reported in the presentations given and the posters made available at ACMG’s Annual Meeting; failure of the Stratys system to unlock research advancements; failure of laboratories to adopt OGM; the ability of our OGM solutions to offer the anticipated benefits for and contributions to the areas reported in the presentations given and posters made available at the ACMG’s 2024 Annual Meeting; future study results contradicting the results reported in the presentations given and posters made available at the ACMG’s 2024 Annual Meeting; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2023 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

CONTACTSCompany Contact:Erik Holmlin, CEOBionano Genomics, Inc.+1 (858) 888-7610eholmlin@bionano.com

Investor Relations:David HolmesGilmartin Group+1 (858) 888-7625IR@bionano.com